bapineuzumab
Sponsors
JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer
Conditions
Alzheimer DiseaseAlzheimer's Disease
Phase 1
Phase 2
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
CompletedNCT00112073
Start: 2005-04-30End: 2008-12-31Updated: 2012-03-14
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
CompletedNCT00663026
Start: 2008-11-30End: 2010-10-31Updated: 2013-11-15
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
TerminatedNCT00916617
Start: 2009-06-30End: 2012-09-30Updated: 2017-06-01
Phase 3
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
TerminatedNCT00667810
Start: 2008-06-30End: 2013-08-31Updated: 2016-01-08
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
TerminatedNCT00676143
Start: 2008-01-31End: 2012-11-30Updated: 2016-06-10
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
TerminatedNCT00937352
Start: 2009-07-31End: 2012-09-30Updated: 2013-12-20